Fig. 2From: Key regulators of sensitivity to immunomodulatory drugs in cancer treatmentMolecular mechanism of IMiD activity. IMiDs bind CRL4CRBN to recruit multiple neosubstrates for ubiquitination and proteasomal degradation, resulting in pleiotropic effects. CUL4, Cullin 4; Ub, ubiquitinBack to article page